Ajanta Pharma Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Ajanta Pharma de 18% y 11.9% por año respectivamente. Se prevé que el BPA crezca en un 18.1% al año. Se espera que la rentabilidad financiera sea de 22.2% en 3 años.
Información clave
18.0%
Tasa de crecimiento de los beneficios
18.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 18.8% |
| Tasa de crecimiento de los ingresos | 11.9% |
| Rentabilidad financiera futura | 22.2% |
| Cobertura de analistas | Good |
| Última actualización | 19 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend
Dec 13Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?
Dec 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting
Nov 19Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2026 | 52,743 | 11,143 | 10,112 | N/A | 9 |
| 3/31/2025 | 47,094 | 9,503 | 6,990 | N/A | 9 |
| 3/31/2024 | 42,008 | 8,080 | 6,081 | N/A | 10 |
| 12/31/2023 | 40,365 | 7,357 | N/A | N/A | N/A |
| 9/30/2023 | 39,031 | 6,602 | 6,610 | 8,199 | N/A |
| 6/30/2023 | 38,128 | 6,215 | N/A | N/A | N/A |
| 3/31/2023 | 37,426 | 5,880 | 6,085 | 7,918 | N/A |
| 12/31/2022 | 37,311 | 6,169 | N/A | N/A | N/A |
| 9/30/2022 | 35,972 | 6,742 | 5,027 | 6,613 | N/A |
| 6/30/2022 | 35,439 | 7,136 | N/A | N/A | N/A |
| 3/31/2022 | 33,410 | 7,127 | 4,129 | 5,617 | N/A |
| 12/31/2021 | 32,275 | 7,207 | N/A | N/A | N/A |
| 9/30/2021 | 31,384 | 7,056 | 3,607 | 5,379 | N/A |
| 6/30/2021 | 29,695 | 6,799 | N/A | N/A | N/A |
| 3/31/2021 | 28,897 | 6,539 | 4,047 | 5,763 | N/A |
| 12/31/2020 | 28,148 | 6,238 | N/A | N/A | N/A |
| 9/30/2020 | 27,173 | 5,547 | 3,593 | 5,334 | N/A |
| 6/30/2020 | 26,441 | 5,008 | N/A | N/A | N/A |
| 3/31/2020 | 25,879 | 4,677 | 2,174 | 4,568 | N/A |
| 12/31/2019 | 24,211 | 4,274 | N/A | N/A | N/A |
| 9/30/2019 | 22,550 | 3,868 | 1,451 | 4,409 | N/A |
| 6/30/2019 | 21,563 | 3,958 | N/A | N/A | N/A |
| 3/31/2019 | 20,554 | 3,870 | 315 | 3,745 | N/A |
| 12/31/2018 | 20,654 | 3,926 | N/A | N/A | N/A |
| 9/30/2018 | 21,674 | 4,731 | N/A | N/A | N/A |
| 6/30/2018 | 21,636 | 4,796 | N/A | N/A | N/A |
| 3/31/2018 | 21,258 | 4,686 | 184 | 2,811 | N/A |
| 12/31/2017 | 20,590 | 4,882 | N/A | N/A | N/A |
| 9/30/2017 | 20,050 | 4,833 | N/A | N/A | N/A |
| 6/30/2017 | 19,805 | 4,821 | N/A | N/A | N/A |
| 3/31/2017 | 19,833 | 5,068 | N/A | 6,093 | N/A |
| 12/31/2016 | 19,386 | 4,908 | N/A | N/A | N/A |
| 9/30/2016 | 18,821 | 4,622 | N/A | N/A | N/A |
| 6/30/2016 | 18,072 | 4,350 | N/A | N/A | N/A |
| 3/31/2016 | 17,340 | 4,156 | N/A | 3,261 | N/A |
| 12/31/2015 | 16,809 | 3,692 | N/A | N/A | N/A |
| 9/30/2015 | 16,160 | 3,510 | N/A | N/A | N/A |
| 6/30/2015 | 15,502 | 3,340 | N/A | N/A | N/A |
| 3/31/2015 | 14,736 | 3,099 | N/A | 2,794 | N/A |
| 3/31/2014 | 12,083 | 2,339 | N/A | 2,124 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18% al año) de AJANTPHARM es superior a la tasa de ahorro (6.7%).
Beneficios vs. Mercado: Se prevé que los beneficios (18% al año) de AJANTPHARM crezcan más rápidamente que el mercado Indian (17.9% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de AJANTPHARM crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (11.9% al año) de AJANTPHARM crezcan más rápidamente que los del mercado Indian (10.3% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 11.9% al año) de AJANTPHARM crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de AJANTPHARM sea alta dentro de 3 años (22.2%)